Filings under BHVN by Biohaven Pharmaceutical Holding Co Ltd. (CIK 0001689813) from May 9, 2017 to Oct 3, 2022 belong to a different issuer and are not shown.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 28, 2026 | Hugin Robert J | Director | Grant(A) | 69K | — | $0 |
| Apr 28, 2026 | Childs John W | Director | Grant(A) | 69K | — | $0 |
| Apr 28, 2026 | Mehta Kishan | Director | Grant(A) | 69K | — | $0 |
| Apr 28, 2026 | Heffernan Michael Thomas | Director | Grant(A) | 69K | — | $0 |
| Apr 28, 2026 | Bailey Gregory | Director | Grant(A) | 69K | — | $0 |
| Apr 28, 2026 | Antonijevic Irina | Director | Grant(A) | 69K | — | $0 |
| Apr 28, 2026 | Gregory Julia P | Director | Grant(A) | 69K | — | $0 |
| Mar 17, 2026 | Mehta Kishan | Director | Gift(G) | 17K | — | $0 |
| Mar 17, 2026 | Mehta Kishan | Director | Gift(G) | 17K | — | $0 |
| Feb 27, 2026 | Gentile Kimberly | SVP, Clinical Operations | Grant(A) | 175K | — | $0 |
| Feb 27, 2026 | Buten Matthew | Chief Financial Officer | Grant(A) | 175K | — | $0 |
| Feb 27, 2026 | Clark George C. | VP, Chief Accounting Officer | Grant(A) | 50K | — | $0 |
| Feb 27, 2026 | Car Bruce | Chief Scientific Officer | Grant(A) | 175K | — | $0 |
| Feb 27, 2026 | Coric Vlad | Chief Executive Officer, Director | Grant(A) | 550K | — | $0 |
| Jan 5, 2026 | Car Bruce | Chief Scientific Officer | Option exercise(M) | 5K | — | $0 |
| Jan 5, 2026 | Coric Vlad | Chief Executive Officer, Director | Tax withholding(F) | 7K | $9.93 | $74K |
| Jan 5, 2026 | Buten Matthew | Chief Financial Officer | Option exercise(M) | 4K | — | $0 |
| Jan 5, 2026 | Coric Vlad | Chief Executive Officer, Director | Option exercise(M) | 14K | — | $0 |
| Jan 5, 2026 | Buten Matthew | Chief Financial Officer | Tax withholding(F) | 3K | $9.93 | $26K |
| Jan 5, 2026 | Buten Matthew | Chief Financial Officer | Option exercise(M) | 4K | — | $0 |
| Jan 5, 2026 | Gentile Kimberly | SVP, Clinical Operations | Tax withholding(F) | 2K | $9.93 | $19K |
| Jan 5, 2026 | Gentile Kimberly | SVP, Clinical Operations | Option exercise(M) | 4K | — | $0 |
| Jan 5, 2026 | Clark George C. | VP, Chief Accounting Officer | Option exercise(M) | 3K | — | $0 |
| Jan 5, 2026 | Car Bruce | Chief Scientific Officer | Option exercise(M) | 5K | — | $0 |
| Jan 5, 2026 | Car Bruce | Chief Scientific Officer | Tax withholding(F) | 2K | $9.93 | $24K |
| Jan 5, 2026 | Clark George C. | VP, Chief Accounting Officer | Tax withholding(F) | 1K | $9.93 | $11K |
| Jan 5, 2026 | Coric Vlad | Chief Executive Officer, Director | Option exercise(M) | 14K | — | $0 |
| Jan 5, 2026 | Gentile Kimberly | SVP, Clinical Operations | Option exercise(M) | 4K | — | $0 |
| Jan 5, 2026 | Clark George C. | VP, Chief Accounting Officer | Option exercise(M) | 3K | — | $0 |
| Nov 17, 2025 | Clark George C. | VP, Chief Accounting Officer | Buy(P) | 17K | $8.52 | $145K |
| Nov 13, 2025 | Coric Vlad | Chief Executive Officer, Director | Buy(P) | 333K | $7.50 | $2.5M |
| Nov 13, 2025 | Coric Vlad | Chief Executive Officer, Director | Buy(P) | 333K | $7.50 | $2.5M |
| Nov 13, 2025 | Childs John W | Director | Buy(P) | 3.3M | $7.50 | $25.0M |
| Nov 13, 2025 | Bailey Gregory | Director | Buy(P) | 400K | $7.50 | $3.0M |
| May 5, 2025 | Childs John W | Director | Grant(A) | 32K | — | $0 |
| May 5, 2025 | Hugin Robert J | Director | Grant(A) | 32K | — | $0 |
| May 5, 2025 | Gregory Julia P | Director | Grant(A) | 32K | — | $0 |
| May 5, 2025 | Mehta Kishan | Director | Grant(A) | 32K | — | $0 |
| May 5, 2025 | Bailey Gregory | Director | Grant(A) | 32K | — | $0 |
| May 5, 2025 | Antonijevic Irina | Director | Grant(A) | 32K | — | $0 |
| May 5, 2025 | Heffernan Michael Thomas | Director | Grant(A) | 32K | — | $0 |
| Mar 4, 2025 | Childs John W | Director | Buy(P) | 28K | $30.43 | $864K |
| Jan 5, 2025 | Clark George C. | VP, Chief Accounting Officer | Option exercise(M) | 3K | — | $0 |
| Jan 5, 2025 | Car Bruce | Chief Scientific Officer | Option exercise(M) | 5K | — | $0 |
| Jan 5, 2025 | Coric Vlad | Chief Executive Officer, Director | Tax withholding(F) | 7K | $38.64 | $263K |
| Jan 5, 2025 | Car Bruce | Chief Scientific Officer | Grant(A) | 19K | — | $0 |
| Jan 5, 2025 | Car Bruce | Chief Scientific Officer | Grant(A) | 112K | — | $0 |
| Jan 5, 2025 | Car Bruce | Chief Scientific Officer | Option exercise(M) | 5K | — | $0 |
| Jan 5, 2025 | Gentile Kimberly | SVP, Clinical Operations | Grant(A) | 91K | — | $0 |
| Jan 5, 2025 | Gentile Kimberly | SVP, Clinical Operations | Option exercise(M) | 4K | — | $0 |
| Jan 5, 2025 | Gentile Kimberly | SVP, Clinical Operations | Option exercise(M) | 4K | — | $0 |
| Jan 5, 2025 | Gentile Kimberly | SVP, Clinical Operations | Tax withholding(F) | 2K | $38.64 | $76K |
| Jan 5, 2025 | Clark George C. | VP, Chief Accounting Officer | Grant(A) | 10K | — | $0 |
| Jan 5, 2025 | Gentile Kimberly | SVP, Clinical Operations | Grant(A) | 15K | — | $0 |
| Jan 5, 2025 | Clark George C. | VP, Chief Accounting Officer | Grant(A) | 30K | — | $0 |
| Jan 5, 2025 | Clark George C. | VP, Chief Accounting Officer | Option exercise(M) | 3K | — | $0 |
| Jan 5, 2025 | Clark George C. | VP, Chief Accounting Officer | Tax withholding(F) | 1K | $38.64 | $43K |
| Jan 5, 2025 | Buten Matthew | Chief Financial Officer | Grant(A) | 104K | — | $0 |
| Jan 5, 2025 | Buten Matthew | Chief Financial Officer | Option exercise(M) | 4K | — | $0 |
| Jan 5, 2025 | Buten Matthew | Chief Financial Officer | Grant(A) | 17K | — | $0 |
| Jan 5, 2025 | Coric Vlad | Chief Executive Officer, Director | Option exercise(M) | 14K | — | $0 |
| Jan 5, 2025 | Car Bruce | Chief Scientific Officer | Tax withholding(F) | 2K | $38.64 | $90K |
| Jan 5, 2025 | Buten Matthew | Chief Financial Officer | Tax withholding(F) | 3K | $38.64 | $99K |
| Jan 5, 2025 | Buten Matthew | Chief Financial Officer | Option exercise(M) | 4K | — | $0 |
| Jan 5, 2025 | Coric Vlad | Chief Executive Officer, Director | Grant(A) | 57K | — | $0 |
| Jan 5, 2025 | Coric Vlad | Chief Executive Officer, Director | Grant(A) | 343K | — | $0 |
| Jan 5, 2025 | Coric Vlad | Chief Executive Officer, Director | Option exercise(M) | 14K | — | $0 |
| Dec 30, 2024 | Childs John W | Director | Buy(P) | 29K | $35.94 | $1.0M |
| Oct 2, 2024 | Childs John W | Director | Buy(P) | 21K | $47.50 | $1000K |
| Oct 2, 2024 | Coric Vlad | Chief Executive Officer, Director | Buy(P) | 21K | $47.50 | $1000K |
| Sep 24, 2024 | Bailey Gregory | Director | Buy(P) | 5K | $44.19 | $221K |
| Jul 18, 2024 | Childs John W | Director | Buy(P) | 28K | $35.67 | $1.0M |
| Jun 17, 2024 | Car Bruce | Chief Scientific Officer | Buy(P) | 30K | $33.58 | $1.0M |
| May 30, 2024 | Childs John W | Director | Buy(P) | 28K | $35.58 | $996K |
| May 13, 2024 | Childs John W | Director | Buy(P) | 29K | $35.17 | $1.0M |
| May 13, 2024 | Bailey Gregory | Director | Buy(P) | 15K | $34.19 | $513K |
| Apr 30, 2024 | Mehta Kishan | Director | Grant(A) | 17K | — | $0 |
| Apr 30, 2024 | Heffernan Michael Thomas | Director | Grant(A) | 17K | — | $0 |
| Apr 30, 2024 | Gregory Julia P | Director | Grant(A) | 17K | — | $0 |
| Apr 30, 2024 | Hugin Robert J | Director | Grant(A) | 17K | — | $0 |
| Apr 30, 2024 | Antonijevic Irina | Director | Grant(A) | 17K | — | $0 |
| Apr 30, 2024 | Childs John W | Director | Grant(A) | 17K | — | $0 |
| Apr 30, 2024 | Bailey Gregory | Director | Grant(A) | 17K | — | $0 |
| Apr 24, 2024 | Bailey Gregory | Director | Buy(P) | 26K | $39.18 | $999K |
| Apr 22, 2024 | Bailey Gregory | Director | Buy(P) | 49K | $41.00 | $2.0M |
| Apr 22, 2024 | Coric Vlad | Chief Executive Officer, Director | Buy(P) | 122K | $41.00 | $5.0M |
| Apr 22, 2024 | Childs John W | Director | Buy(P) | 73K | $41.00 | $3.0M |
| Apr 5, 2024 | Coric Vlad | Chief Executive Officer, Director | Grant(A) | 232 | — | — |
| Apr 5, 2024 | Coric Vlad | Chief Executive Officer, Director | Grant(A) | 231 | — | — |
| Apr 5, 2024 | Childs John W | Director | Grant(A) | 2K | — | — |
| Apr 5, 2024 | Coric Vlad | Chief Executive Officer, Director | Grant(A) | 231 | — | — |
| Mar 8, 2024 | Coric Vlad | Chief Executive Officer, Director | Grant(A) | 2K | — | — |
| Mar 8, 2024 | Childs John W | Director | Grant(A) | 19K | — | — |
| Mar 8, 2024 | Coric Vlad | Chief Executive Officer, Director | Grant(A) | 2K | — | — |
| Mar 8, 2024 | Coric Vlad | Chief Executive Officer, Director | Grant(A) | 2K | — | — |
| Jan 8, 2024 | Childs John W | Director | Other(J) | 49K | — | — |
| Jan 8, 2024 | Coric Vlad | Chief Executive Officer, Director | Grant(A) | 5K | — | — |
| Jan 8, 2024 | Coric Vlad | Chief Executive Officer, Director | Grant(A) | 5K | — | — |
| Jan 8, 2024 | Coric Vlad | Chief Executive Officer, Director | Grant(A) | 5K | — | — |
| Jan 2, 2024 | Coric Vlad | Chief Executive Officer, Director | Grant(A) | 275K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Biohaven Ltd., SEC CIK 0001935979. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under BHVN and shows every filing by that issuer. Earlier filings under the same symbol by another issuer are left out.
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-12. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for BHVN